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ABSTRACT
Introduction: Pseudomonas aeruginosa is a leading cause of ventilator-associated pneumonia 
(VAP) and exhibits high rates of resistance to several antimicrobial drugs. The carbapenens are 
usually the drugs of choice against this microorganism. However, the carbapenem resistance 
has increased among these strains worldwide. The presence of metallo-β-lactamases (MBL) 
has been pointed out as a major mechanism of resistance among these strains. No previous 
study addressed outcomes of respiratory infections caused by these strains. Methods: Our 
group sought to analyze the epidemiology and clinical outcomes of patients with VAP caused 
by imipenem-resistant P. aeruginosa. A total of 29 clinical isolates of carbapenem-resistant 
Pseudomonas aeruginosa were screened for metallo-β-lactamase (MBL) genes. Results: 
Demographic and clinical variables were similar between the SPM-1-producing and non-
SPM-1-producing group. Five (17.2%) isolates were positive for blaSPM-1. No other MBL gene 
was found. All patients were treated with polymyxin B. The infection-related mortality was 
40% and 54.2% for SPM-1-producing and -non-producing isolates, respectively. Conclusions: 
There were no differences in epidemiological and clinical outcomes between the two groups.
Keywords: Pseudomonas aeruginosa. Antimicrobial resistance. Outcome.
RESUMO
Introdução: Pseudomonas aeruginosa é uma importante causa de pneumonia associada à 
ventilação mecânica (PAV) e exibe altas taxas de resistência a vários antimicrobianos. Os 
carbapenens são usualmente as drogas de escolha para esse microorganismo. Contudo, a 
resistência a carbapenens tem crescido entre essas amostras em todo o mundo. A presença de 
metalo- β-lactamase (MBL) tem sido apontado como um importante mecanismo de resistência 
nessas cepas. Nenhum estudo prévio avaliou desfechos clínicos de infecções respiratórias 
causadas por essas amostras Métodos: Nosso grupo analisou a epidemiologia e evolução 
clínica de episódios de PAV causada por P. aeruginosa resistente a imipenem. Um total de vinte 
e nove isolados clínicos de Pseudomonas aeruginosa resistente a carbapenem foram avaliados 
quanto à presença de genes para metalo-β-lactamase (MBL). Resultados: Variáveis clínicas 
e demográficas foram similares entre o grupo produtor de SPM-1 e o não-produtor. Cinco 
(17,2%) isolados foram positivos para blaSPM-1. Nenhum outro gene para MBL foi encontrado. 
Todos os pacientes foram tratados com polimixina B. A mortalidade relacionada à infecção 
foi de 40% e 50% respectivamente para os isolados produtores de SPM-1 e não-produtores 
de SPM-1. Conclusões: Nao houve diferença entre os dados epidemiológicos e a evolução 
clínica entre os dois grupos.
Palavras-chaves: Pseudomonas aeruginosa. Resistência antimicrobiana. Desfecho.
Pseudomonas aeruginosa exhibits high rates 
of resistance to several antimicrobial drugs. The 
carbapenems are usually the drugs that provide the 
best coverage against this microorganism. However, 
the carbapenem resistance has increased among 
these strains1. The presence of metallo-β-lactamases 
(MBL) has been pointed out as a major mechanism 
of this resistance2, 3.
The São Paulo Metallo-β-lactamase (SPM-1) 
was described in São Paulo, in 2001. Since then, 
a SPM-1-producing endemic clone has been 
predominantly reported in several regions in 
Brazil4, 5. Its prevalence among carbapenem-resistant 
Pseudomonas aeruginosa (CRPA) isolates has reached 
rates of 34.8%5. However, the clinical outcome of these 
infections compared with infections caused by non-
SPM-1-harboring isolates has not been reported6, 7. 
Indeed, to our knowledge, no previous study has 
specifically addressed outcomes of respiratory tract 
infections caused by these strains.
The present study aimed to investigate the 
prevalence of blaSPM-1 gene among imipenem-
resistant Pseudomonas aeruginosa responsible for 
episodes of ventilator-associated pneumonia (VAP), 
as well as the clinical outcomes of these infections 
compared with episodes of VAP caused by non-
SPM-1-producing isolates.
METHODS
This study was carried out at Hospital São Paulo, 
a 750-bed teaching hospital in São Paulo, Brazil. 
It was designed to assess the clinical outcome of 
patients with ventilator-associated pneumonia 
(VAP) caused by imipenem-resistant SPM-1-
producing Pseudomonas aeruginosa. All adult patients 
for whom respiratory tract cultures had grown CRPA 
from January 1, 2004 to December 31, 2006 and had 
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TABLE 1 - Clinical and demographic characteristics of episodes of ventilator-
associated pneumonia caused by imipenem-resistant Pseudomonas aeruginosa.
 SPM-1 Without SPM-1
  (n=5)  (n=24) 
Variable n % n % p
Age (years) 63 51 0.24
Duration of hospital stay, days 25 29 0.88
Duration of ICU stay, days 24 22 0.63
Number of antibiotics 5 4 0.32
Duration of mechanical ventilation, days 24 16 0.44
APACHE II score, mean 15 15 0.67
Time under antibiotics 31 27 0.41
Female gender 4 80.0 7 29.1 0.05
Surgery 2 40.0 17 70.8 0.30
Previous hospitalization 0 0.0 6 25.0 0.55
Corticosteroid use 2 40.0 12 50.0 >0.99
Immunossupressive drug use 1 20.0 2 8.3 0.44
Comorbidity
diabetes mellitus 1 20.0 2 8.3 0.44
cirrhosis 0 0.0 3 12.5 >0.99
COPD 0 0.0 5 20.8 0.55
chronic renal failure 1 20.0 3 12.5 0.55
cancer 1 20.0 5 20.8 >0.99
transplant 1 20.0 2 8.3 0.44
Antimicrobial drug use
third-gen chephalosporin 4 80.0 14 58.3 0.62
fourth-gen cephalosporin 3 60.0 9 37.5 0.62
carbapenem 3 60.0 18 75.0 0.59
vancomycin 5 100.0 21 87.5 >0.99
aminoglycoside 1 20.0 6 25.0 >0.99
fluoroquinolone 1 20.0 7 29.2 >0.99
piperacillin-tazobactam 0 0.0 3 12.5 >0.99
SPM: São Paulo metallo-β-lactamase, ICU: intensive care unit; APACHE II: 
acute physiology and chronic health evaluation II; COPD: chronic obstructive 
pulmonary disease.
TABLE 2 - Comparative analysis of factors related to clinical outcome.
 SPM-1 Without SPM-1
 (n=5) (n=24)
Variable n % n % p
Presence of septic shock 2 40.0 15 62.5 0.62
Presence of ARDS 2 40.0 7 29.2 0.63
Bacteremia 1 20.0 2 8.3 0.44
Acute renal failure 0 0.0 2 8.3 >0.99
Infection-related mortality 2 40.0 13 54.2 0.65
In-hospital mortality 3 60.0 18 75.0 0.59
SPM: São Paulo Metallo-β-lactamase, ARDS: acute respiratory distress syndrome.
received a diagnosis of VAP were eligible for inclusion in the study. 
Only the first episode of pneumonia was included. Polymicrobial 
VAPs were excluded. All episodes fulfilled the criteria for nosocomial 
infection as defined by the Centers for Disease Control and 
Prevention (CDC).
Patients with VAP caused by SPM-1-producing strains were 
compared to patients with VAP caused by non-SPM-1-producing 
strains selected on the basis of hospital unit and date of admission 
(±30 days). From the in-patient medical record, we collected 
demographic, clinical, and microbiological data. Infection-related 
mortality was considered present when a patient died within 14 days 
of the diagnosis of pneumonia and the death could not be directly 
attributed to any other cause. Several demographic and clinical 
variables were evaluated.
The microbiological analysis of respiratory samples was conducted 
using conventional techniques. The cutoff for the bronchoalveolar 
lavage (BAL) and for the tracheal aspirate was 104 colony-forming 
units (CFU/)mL and 105 CFU/mL, respectively. The susceptibility 
testing was performed by the disk diffusion technique8. Minimum 
inhibitory concentration (MIC) determinations for carbapenems 
and polymyxin B were conducted using the agar dilution technique9. 
Isolates were considered susceptible to polymyxin B if the MIC was 
≤2µg/ml. P. aeruginosa isolates were screened for the presence of 
MBLs by using Multiplex PCR. The following genes were searched: 
blaIMP, blaVIM, blaGIM-1, blaSIM-1, and blaSPM-1
10.
Ethical considerations
The study was approved by the local Ethics Committee.
A total of 29 patients with VAP caused by CRPA were identified. 
The clinical and demographic characteristics of these patients are 
shown in Table 1. Demographic and clinical variables were similar 
between the SPM-1-producing and non-SPM-1-producing isolates. 
The mean ages were 63 years and 51 years for the SPM-1-producing 
and non-SPM-1-producing groups, respectively. The mean durations 
of ICU stay were 25 and 29 days for the SPM-1-producing and 
non-SPM-1-producing groups, respectively. Three (60%) patients 
and 18 (75%) patients in the SPM-1-producing and non-SPM-1-
producing groups, respectively, utilized carbapenems before the 
diagnosis of VAP.
Patient outcomes are shown in Table 2. There were no differences 
in the outcome-associated variables between the two groups. All 
patients in both groups were treated with polymyxin B. No combined 
therapy was utilized. In all cases, empirical antimicrobial therapy was 
determined to be adequate. The infection-related mortality rates were 
40% and 54.2% in the SPM-1-producing and non-SPM-1-producing 
groups, respectively. No differences in the infection-related mortality 
rates and in the in-hospital mortality rates were observed between 
the two groups.
All SPM-1-producing isolates were resistant to all beta-lactams, 
fluoroquinolones, and aminoglycosides. Only polymyxin B remained 
susceptible. The MIC50/MIC90 for imipenem, meropenem, and 
polymyxin B were 16/≥32μg/mL, 16/≥32μg/mL and 1/2μg/mL, 
respectively. Only five samples (17.2%) showed PCR amplification 
product for the blaSPM-1 gene. No other metallo-β-lactamase was 
detected.
The present study aimed to identify outcome differences 
between episodes of VAP caused by carbapenem-resistant SPM-1-
producing and -non-producing Pseudomonas aeruginosa. As far as 
we know, this is the first work specifically addressing this subject. 
Furthermore, few studies analyzed risk factors for the presence 
of SPM-1 among Pseudomonas aeruginosa (PA) isolates in Brazil. 
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Noue et al., found the use of quinolones as the sole independent 
predictor of colonization and/or infection by blaSPM multi-drug-
resistant Pseudomonas aeruginosa11. Other recent study described 
an outbreak of imipenem-resistant MBL-producing Pseudomonas 
aeruginosa in an adult intensive care unit (ICU). Pneumonia was 
the predominant infection (85%), and only SPM-1 was identified 
in 15 specimens analyzed. Advanced age, mechanical ventilation, 
tracheostomy, and previous imipenem use were significant risk 
factors for infection12.
Our findings demonstrate that there are no differences between 
SPM-1-producing and -non-producing strains causing VAP. The 
low incidence of SPM-1-producing strains demonstrates that other 
resistance mechanisms are involved, such as permeability mutations 
or the up-regulation of efflux systems13, 14. Recently, we demonstrated 
the importance of efflux pumps and AmpC hiperexpression among 
Pseudomonas aeruginosa strains in our setting15.
At our hospital, the isolation of CRPA has been kept at an average 
rate of 60% over the past few years, and the lower respiratory tract has 
been its major site16. In addition, a previous study undertaken at our 
hospital demonstrated that 43.9% of these strains harbored MBLs, 
mostly SPM-1 (55.6%)14. On the other hand, our study demonstrated 
a lower percentage of MBL-producing strains in respiratory tract 
when compared with previous studies focused on blood isolates5, 7, 14. 
Interestingly, this finding was previously observed in a descriptive 
study at our setting6.
Marra et al., described seven patients with bloodstream infections 
caused by MBL-producing CRPA (4 out 7 were SPM-1)6. Infection-
related mortality was very high (71.4%), but the respiratory tract 
was the infection site in only two patients in this study. Only one 
of these respiratory strains was positive for the presence of blaSPM-1. 
Other recent study investigated the outcomes of 86 MBL-producing 
Pseudomonas aeruginosa infections7. The presence of MBL-producing 
strains was associated to higher in-hospital mortality rates when 
compared with non-MBL-producing strains (51.2% versus 32.1%). 
Severe sepsis or septic shock and age were associated with a poor 
outcome in this study. However, only 14 isolates were tested for the 
presence of MBL genes, and all were positive for the presence of 
blaSPM-1. All other strains were submitted only to phenotypic test by 
disc diffusion with 2-mercaptopropionic acid. In our study, the in-
hospital mortality rates were higher mainly in the non-SPM-1 group. 
All patients in our study were critically ill with higher APACHE II 
scores. A lot of them presented septic shock and acute respiratory 
distress syndrome (ARDS). Thus, we think that these factors may 
justify the high mortality rates. Otherwise, there were no differences 
between these outcome variables between the two groups.
Our study has limitations. First, the small sample size limited our 
capacity to detect differences between the two groups. Finally, it is 
plausible that our findings may not be generalized to other settings. 
On the other hand, it is important to better understand the outcome 
of these infections, as recently, SPM-1 was reported in Switzerland. 
This is the first reported case of a Pseudomonas aeruginosa isolate 
possessing blaSPM-1 outside Brazil
17.
In conclusion, our study found no differences in clinical outcomes 
between SPM-1-producing and non-SPM-1-producing episodes of 
VAP. A reduced number of respiratory isolates harbored MBL genes 
(17.2%). The blaSPM-1 was the only gene identified among the MBL-
positive strains. A relatively high infection-related mortality rate was 
also observed. Further studies are needed to confirm these results.
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